Bortezomib-based induction followed by high-dose melphalan (200 mg/m2) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed multiple myeloma. We aimed to evaluate the efficacy and safety of different carfilzomib-based induction and consolidation approaches with or without transplantation and of maintenance treatment with carfilzomib plus lenalidomide versus lenalidomide alone in newly diagnosed multiple myeloma.

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Gay, Francesca
Co-first
;
Bertamini, Luca;D'Agostino, Mattia;Capra, Andrea;Boccadoro, Mario
Last
2021-01-01

Abstract

Bortezomib-based induction followed by high-dose melphalan (200 mg/m2) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed multiple myeloma. We aimed to evaluate the efficacy and safety of different carfilzomib-based induction and consolidation approaches with or without transplantation and of maintenance treatment with carfilzomib plus lenalidomide versus lenalidomide alone in newly diagnosed multiple myeloma.
2021
22
12
1705
1720
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00535-0/ppt
https://doi.org/10.1016/s1470-2045(21)00535-0
multiple myeloma, newly diagnosed, carfilzomib, cyclophosphamide, lenalidomide, dexamethasone, induction treatment, autologous stem-cell transplantation, maintenance treatment, phase 2, trial
Gay, Francesca; Musto, Pellegrino; Rota-Scalabrini, Delia; Bertamini, Luca; Belotti, Angelo; Galli, Monica; Offidani, Massimo; Zamagni, Elena; Ledda, ...espandi
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn and Suppl Appendix] - Gay et al - 2021 - Lancet Oncol - FORTE trial.pdf

Accesso riservato

Descrizione: [Restricted access - Published Vsn. and Suppl. Appendix 1 and 2] Gay F. et al. Lancet Oncol . 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. © 2021 Elsevier Ltd. All rights reserved. Available at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00535-0/ppt | https://doi.org/10.1016/s1470-2045(21)00535-0
Tipo di file: PDF EDITORIALE
Dimensione 5.72 MB
Formato Adobe PDF
5.72 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
[Author Vsn and Suppl Appendix] Gay et al - 2021 - Lancet Oncol - FORTE trial - Post-print c.pdf

Accesso riservato

Descrizione: [Restricted Access - Post-print Author Vsn. and Suppl. Appendix 1 and 2] Gay F. et al. Lancet Oncol . 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. © 2021 Elsevier Ltd. All rights reserved. The published version is available at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00535-0/ppt | https://doi.org/10.1016/s1470-2045(21)00535-0
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 3.73 MB
Formato Adobe PDF
3.73 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
[Pre-print Vsn and Suppl Appendix] Gay et al - 2021 - Lancet Oncol - FORTE trial - Pre-print.pdf

Accesso aperto

Descrizione: [Pre-print Vsn. and Suppl. Appendix] Gay F. et al. Lancet Oncol . 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. © 2021 Elsevier Ltd. All rights reserved. The published version is available at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00535-0/ppt | https://doi.org/10.1016/s1470-2045(21)00535-0
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 4.32 MB
Formato Adobe PDF
4.32 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1819042
Citazioni
  • ???jsp.display-item.citation.pmc??? 52
  • Scopus 139
  • ???jsp.display-item.citation.isi??? 128
social impact